Recent advances in porous MOFs and their hybrids for photothermal cancer therapy-Reference-Cited by-同舟云学术

Recent advances in porous MOFs and their hybrids for photothermal cancer therapy

Published:2022 Issue:23 Volume:51 Page:8938-8944
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Su Jia¹,Jing Peng¹,Jiang Ke¹²^ORCID,Du Jingjing³

Affiliation:

1. Key Laboratory of Food Nutrition and Functional Food of Hainan Province, School of Food Science and Engineering, Hainan University, Haikou 570228, China

2. State Key Laboratory of Silicon Materials, Zhejiang University, Hangzhou 310027, China

3. Analytical & Testing Center, Hainan University, Haikou 570228, China

Abstract

We mainly summarize the recent advances of MOFs in photothermal combined cancer therapy and hope that this review will stimulate more interesting explorations in MOFs for photothermal therapy.

Funder

Key Research and Development Project of Hainan Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/DT/D2DT01039A

Reference87 articles.

1. Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy

2. Photothermal therapy

3. Two‐Dimensional Nanomaterials for Photothermal Therapy

4. Photodynamic therapy for cancer

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amorphous metal–organic frameworks: Pioneering frontiers in cancer diagnostics and therapeutics;Chemical Engineering Journal;2024-07

2. A critical review on metal-organic frameworks (MOFs) based nanomaterials for biomedical applications: Designing, recent trends, challenges, and prospects;Heliyon;2024-02

3. Heterometallic MIL-125(Ti–Al) frameworks for electrochemical determination of ascorbic acid, dopamine and uric acid;Dalton Transactions;2024

4. Recent advances in metal–organic frameworks for stimuli-responsive drug delivery;Nanoscale;2024

5. Clinical trials, patents, and marketed products of nanocurcumin-based anticancer drug delivery systems;Curcumin-Based Nanomedicines as Cancer Therapeutics;2024